State of the Art Antithrombotic Therapies for Coronary and Peripheral Atherosclerosis-Let's Talk About a Personalized Approach to Antithrombotic Therapies

Video Transcription

Video Summary

In this video discussion, experts discuss the use of antithrombotic therapies for coronary artery disease (CAD) and peripheral arterial disease (PAD). The experts explain that while CAD and PAD are both atherosclerotic diseases, they do have important differences. For CAD, the focus is on acute events, such as heart attacks, while PAD is a chronic condition with a higher risk of limb events. The discussion also explores the concept of risk stratification for patients with CAD and PAD. The experts emphasize the importance of considering both major adverse cardiovascular events (MACE) and major adverse limb events (MALE) as potential risks for these patients. The conversation then turns to the topic of antithrombotic therapies. It is noted that while there are established guidelines for CAD, there is still a need for more research and guidelines for PAD. The experts discuss the various treatment options, such as aspirin, statins, and dual antiplatelet therapy (DAPT), and highlight the importance of tailoring treatment to the individual patient. They also discuss the potential role of newer therapies, such as PCSK9 inhibitors and GLP-1 agonists, in reducing amputation and other major adverse limb events in patients with PAD. Overall, the experts emphasize the need for a personalized approach to antithrombotic therapy for CAD and PAD, considering both the cardiovascular and limb risks for each patient.

Keywords

antithrombotic therapies

coronary artery disease

peripheral arterial disease

atherosclerotic diseases

acute events

chronic condition

limb events

risk stratification

personalized approach